Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

54.85USD
18 Apr 2019
Change (% chg)

$-1.74 (-3.07%)
Prev Close
$56.59
Open
$56.35
Day's High
$56.81
Day's Low
$52.56
Volume
387,648
Avg. Vol
255,047
52-wk High
$59.95
52-wk Low
$30.16

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics Prices A $150.0 Million Common Stock Public Offering
Friday, 7 Dec 2018 

Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $150.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

GBT Says FDA Agrees To Review Sickle Cell Drug Under Accelerated Pathway
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES U.S. FDA AGREES WITH ITS PROPOSAL RELATING TO ACCELERATED APPROVAL PATHWAY FOR VOXELOTOR FOR THE TREATMENT OF SICKLE CELL DISEASE AND GBT PLANS TO SUBMIT NEW DRUG APPLICATION (NDA).GLOBAL BLOOD THERAPEUTICS INC - PRE-NDA MEETING TO BE REQUESTED FOR Q1 OF 2019.  Full Article

GBT Q3 Loss Per Share $0.83
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND PROVIDES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.83.Q3 EARNINGS PER SHARE VIEW $-0.86 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $482.1 MILLION AT SEPTEMBER 30, 2018.  Full Article

GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Global Blood Therapeutics Inc ::GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS.GLOBAL BLOOD THERAPEUTICS INC - ENTERED INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD.GLOBAL BLOOD THERAPEUTICS INC - AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF INCLACUMAB.GLOBAL BLOOD THERAPEUTICS INC - GBT WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION OF INCLACUMAB WORLDWIDE.GLOBAL BLOOD THERAPEUTICS INC - ROCHE WILL RECEIVE AN UPFRONT PAYMENT OF $2.0 MILLION FROM GBT.GLOBAL BLOOD THERAPEUTICS INC - ROCHE IS ELIGIBLE TO RECEIVE UP TO ABOUT $125 MILLION IN MILESTONE PAYMENTS FOR SICKLE CELL DISEASE INDICATION.GLOBAL BLOOD THERAPEUTICS INC - GBT HAS ALREADY BEGUN PROCESS OF TECHNOLOGY TRANSFER FROM ROCHE TO A CONTRACT MANUFACTURING ORGANIZATION.GLOBAL BLOOD THERAPEUTICS - EXPECTS SUBMITTING IND APPLICATION TO U.S. FDA FOR INCLACUMAB IN 2021.GLOBAL BLOOD THERAPEUTICS - ADDITIONALLY, ROCHE IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET REVENUES FOR INCLACUMAB.  Full Article

Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock
Friday, 9 Mar 2018 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC-‍PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 4.0 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $54.00 PER SHARE​.  Full Article

Global Blood Therapeutics Announces Proposed Public Offering
Friday, 9 Mar 2018 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.50 MILLION COMMON SHARES.  Full Article

Global Blood Therapeutics Q4 Loss Per Share $0.94
Wednesday, 28 Feb 2018 

Feb 27 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.94.  Full Article

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).  Full Article

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article